CompanyGraph
Shandong Weigao Blood Purification Products Co. Ltd.
603014 · SSE · China
wego-healthcare.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.96B, above the global median of $1.18B
- FinancialsAltman Z-Score 6.69: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.34%
Annual Rate
CNY 0.42Paid semi-annual
Payout Ratio
43.6%Sustainable
Payback Period
53.9 yr
Last Ex-Dividend
Sep 14, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
13.15BCNY1.96B · vs all stocks (USD)
Trailing P/E
26.24xvs Medical Devices peers
Revenue (TTM)
3.76BCNY561.82M · vs all stocks (USD)
Profit Margin
13.07%vs Medical Devices peers
52-Week Change
-17.32%vs all stocks
Forward Annual Dividend Yield
1.34%vs all stocks
Market Capitalization
13.15BCNY1.96B · vs all stocks (USD)
Enterprise Value
10.40BCNY1.55B · vs all stocks (USD)
Trailing P/E
26.24xvs Medical Devices peers
Forward P/E
23.66xvs Medical Devices peers
Price to Sales (TTM)
3.47xvs Medical Devices peers
Price to Book (MRQ)
1.80xvs Medical Devices peers
Enterprise to Revenue
2.76xvs Medical Devices peers
Enterprise to EBITDA
13.01xvs Medical Devices peers
Gross Margin
36.77%vs Medical Devices peers
Profit Margin
13.07%vs Medical Devices peers
Operating Margin
12.20%vs Medical Devices peers
Return on Assets (TTM)
4.07%vs Medical Devices peers
Return on Equity (TTM)
7.01%vs Medical Devices peers
Revenue (TTM)
3.76BCNY561.82M · vs all stocks (USD)
Revenue per Share (TTM)
9.08CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-1.70%vs Medical Devices peers
Gross Profit (TTM)
1.45BCNY215.99M · vs all stocks (USD)
EBITDA (TTM)
545.49MCNY81.46M · vs all stocks (USD)
Net Income (TTM)
491.82MCNY73.44M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
3.30%vs Medical Devices peers
Operating Cash Flow (TTM)
733.56MCNY109.54M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
406.31MCNY60.67M · vs all stocks (USD)
Forward Annual Dividend Rate
0.4200CNYUpdated Sep 22, 2026Forward Annual Dividend Yield
1.34%vs all stocks
Trailing Annual Dividend Rate
0.5708CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
1.81%vs all stocks
Payout Ratio
43.56%vs Medical Devices peers
Minority Interest (Equity)
14.34KCNYFY2025 · Dec 31, 2025Revenue
3.77BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
2.25BCNYFY2025 · Dec 31, 2025Gross Profit
1.52BCNYFY2025 · Dec 31, 2025Operating Income
557.04MCNY83.18M · vs all stocks (USD)
Pre-tax Income
575.82MCNYFY2025 · Dec 31, 2025Income Tax Expense
93.51MCNYFY2025 · Dec 31, 2025Net Income
482.31MCNYFY2025 · Dec 31, 2025EBIT
576.57MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
828.19MCNYFY2025 · Dec 31, 2025Research & Development
143.86MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
398.70MCNYFY2025 · Dec 31, 2025Other Operating Expenses
52.63MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.14MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
743.12KCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
482.31MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-14.34KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
433.92MCNYFY2025 · Dec 31, 2025Free Cash Flow
274.38MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.14BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
482.31MCNYFY2025 · Dec 31, 2025Other Non-cash Items
3.91MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
22.55MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-74.85MCNYFY2025 · Dec 31, 2025Capital Expenditures
-159.54MCNYFY2025 · Dec 31, 2025Purchase of Investments
-10.60BCNYFY2025 · Dec 31, 2025Sale of Investments
9.27BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.49BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-65.83MCNYFY2025 · Dec 31, 2025Other Financing Charges
1.11BCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
1.04BCNYFY2025 · Dec 31, 2025Shares Outstanding
417.75MSharesUpdated Sep 22, 2026Float Shares
65.16MSharesUpdated Sep 22, 2026% Held by Insiders
78.71%vs all stocks
% Held by Institutions
5.17%vs all stocks
Total Cash (MRQ)
2.67BCNY398.97M · vs all stocks (USD)
Total Cash per Share (MRQ)
6.39CNYUpdated Sep 22, 2026Total Debt (MRQ)
20.84MCNY3.11M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0029xvs Medical Devices peers
Current Ratio (MRQ)
3.89xvs Medical Devices peers
Book Value per Share (MRQ)
17.31CNYUpdated Sep 22, 2026Total Assets
8.61BCNY1.29B · vs all stocks (USD)
Total Current Assets
4.67BCNYFY2025 · Dec 31, 2025Total Liabilities
1.49BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.93BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
74.39MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.42BCNYFY2025 · Dec 31, 2025Cash
1.14BCNYFY2025 · Dec 31, 2025Cash Equivalents
442.90MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.58BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.22BCNYFY2025 · Dec 31, 2025Accounts Receivable
862.49MCNYFY2025 · Dec 31, 2025Inventory
823.25MCNYFY2025 · Dec 31, 2025Accounts Payable
570.40MCNYFY2025 · Dec 31, 2025Short-term Debt
2.90MCNYFY2025 · Dec 31, 2025Other Current Liabilities
125.72MCNYFY2025 · Dec 31, 2025Long-term Debt
30.29KCNYFY2025 · Dec 31, 2025Common Stock (Book)
417.75MCNYFY2025 · Dec 31, 2025Retained Earnings
1.73BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
7.12BCNY1.06B · vs all stocks (USD)
52-Week Low
29.70CNYUpdated Sep 22, 202652-Week High
49.01CNYUpdated Sep 22, 202652-Week Change
-17.32%vs all stocks
50-Day MA
32.23CNYUpdated Sep 22, 2026200-Day MA
36.47CNYUpdated Sep 22, 2026Avg 10-Day Volume
837.11KSharesUpdated Sep 22, 2026Avg 30-Day Volume
1.25MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
1.19CNYUpdated Sep 22, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How is this stock valued?
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 6.69: safe zoneNotable
Altman Z-Score: 6.69
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.96B, above the global median of $1.18BNotable
Market cap (USD): 1,963,199,765.844Global Median: 1,180,223,658.953
Revenue is $561.82M, above the global median of $548.88MNotable
Revenue (USD): 561,821,759.813Global Median: 548,883,780.48
Levered free cash flow is $60.67M, above the global median of $18.73MNotable
Levered free cash flow (USD): 60,674,738.21Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Biohaven Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Establishment Labs Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sarepta Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nektar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Agios Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zymeworks Inc.
Tier 1ProductionApproval-Gated PipelineRule
Galapagos NV
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pavella Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Innostar Bio-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Urogen Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hangzhou Shunwang Technology Co., Ltd.
3 interpretationsPrice Below Mean With Profitability And EquityPrice Below Mean With Profitability And Book ValueMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cocreation Grass Co. Ltd.
3 interpretationsPrice Below Mean With Profitability And EquityPrice Below Mean With Profitability And Book ValueMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Finolex Industries Ltd.
3 interpretationsPrice Below Mean With Profitability And EquityPrice Below Mean With Profitability And Book ValueMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities